ENTX — Entera Bio Income Statement
0.000.00%
- $62.62m
- $55.51m
- $0.04m
Annual income statement for Entera Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.571 | 0.134 | 0 | 0.181 | 0.042 |
| Cost of Revenue | |||||
| Gross Profit | 0.198 | 0.033 | 0 | 0.009 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 12.8 | 13.2 | 8.89 | 9.77 | 11.6 |
| Operating Profit | -12.2 | -13 | -8.89 | -9.59 | -11.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -12.2 | -12.9 | -8.86 | -9.53 | -11.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -12.2 | -13.1 | -8.89 | -9.54 | -11.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -12.2 | -13.1 | -8.89 | -9.54 | -11.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12.2 | -13.1 | -8.89 | -9.54 | -11.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.466 | -0.454 | -0.306 | -0.253 | -0.248 |